<p>, /PRNewswire/ -- Arna Pharma Inc 和 Slate Run Pharmaceuticals 宣布他们已签署谅解备忘录，计划创建一个以美国为基地的专业制药合资企业，专注于品牌产品、505(b)(2) 药物和专业仿制药。</p>
<p>该合资企业将 Arna Pharma 的开发能力和产品组合扩展战略与 Slate Run Pharmaceuticals 在美国的商业、监管和供应链基础设施相结合。</p>
<p>&#34;这标志着 Arna Pharma 的一个重要里程碑，也是我们长期战略向前迈出的重要一步，&#34; Arna Pharma Inc 高级副总裁 Ram Iyer 说。&#34;通过将 Arna 的开发专业知识与 Slate Run 经过验证的美国商业和运营基础设施相结合，我们创建了一个独特的平台，能够在高价值治疗领域扩展专业仿制药，并加速市场准入、报销和医生参与。&#34;</p>
<p>Slate Run Pharmaceuticals 成立于 2014 年，已在美国建立了强大的市场基础，拥有一支经验丰富的商业和监管团队。该合资企业将能够高效地在美国市场扩展品牌和专业产品。</p>
<p>&#34;我们很高兴能够团结我们的组织，共同开启这一新篇章，&#34; Slate Run Pharmaceuticals 首席执行官 Michael Plessinger 说。&#34;这种结合增强了我们执行的能力，扩展了我们的产品组合，并继续作为行业的可信赖美国合作伙伴。&#34;</p>
<p>两家组织的领导层将紧密合作，以确保无缝整合，保持运营连续性，并遵循最高标准的监管合规、产品质量和患者护理。</p>
<p>Arna Pharma Inc 和 Slate Run Pharmaceuticals 欢迎与战略合作伙伴、投资者、许可方和投资组合公司进行接触，感兴趣的各方可以与合并后的组织合作，共同执行其增长战略，建立领先的美国专业制药平台。</p>
<p>如需更多信息，请联系：</p>
<ul>
<li><strong><em>Arna Pharma Inc.:</em></strong> Ram Iyer, [email protected]</li>
<li><strong><em>Slate Run Pharmaceuticals LLC</em></strong> : Mike Plessinger, [email protected]</li>
</ul>
<p><strong>关于 Arna Pharma Inc.</strong></p>
<p>美国业务于 2024 年启动，旨在创造一个更健康的世界，Arna Pharma Inc 将专利级创新与智能、可持续的商业实践相结合。由行业专家创立，专注于创新和患者结果，我们对质量和诚信的承诺驱动我们提供安全、有效和可靠的治疗方案。</p>
<p>作为一家全面整合的制药组织，Arna Pharma Inc 提供从配方开发和生产到全球营销和商业化的端到端能力。我们的产品组合强调小众剂型和针对罕见和被忽视疾病的治疗，反映了我们以专业化为重点解决未满足医疗需求的使命。</p>
<p><strong>关于 Slate Run Pharmaceuticals:</strong></p>
<p>Slate Run Pharmaceuticals 成立于 2014 年，在美国仿制药市场建立了强大且不断扩展的存在。公司由一支经验丰富的领导团队领导，团队成员在商业运营、监管事务、质量和供应链管理方面拥有超过 200 年的行业经验。Slate Run 的团队直接参与了广泛的仿制药组合的选择、FDA 批准、商业化和供应，涵盖多个治疗领域。</p>
<p>目前，Slate Run 市场上有超过 30 个产品系列，服务于包括批发商、分销商、药店和医疗服务提供者在内的美国客户。通过严格的产品组合开发、战略制造合作伙伴关系以及对监管合规和供应可靠性的承诺，Slate Run 致力于扩大患者对高质量、可负担药物的获取，同时推动可持续增长。</p>
<p>来源：Slate Run Pharmaceuticals; Arna Pharma Inc。</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI2Jk5ld3NJdGVtSWQ9Q0w5NjcxNCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjYxMzAwUFJfTkVXU19VU1BSX19fX19DTDk2NzE0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI2Jk5ld3NJdGVtSWQ9Q0w5NjcxNCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjYxMzAwUFJfTkVXU19VU1BSX19fX19DTDk2NzE0"/></p>

SLRX

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

<p>Arna Pharma Inc. 和 Slate Run Pharmaceuticals 签署了一份谅解备忘录（MOU），旨在建立一个合资企业，以创建一个规模化的美国专业制药平台。此次合作将利用 Arna 的开发能力和 Slate Run 的商业及监管基础设施，专注于品牌产品、505(b)(2) 药物和专业仿制药。合资企业预计将增强市场准入，并加速在高价值治疗领域推出专业仿制药。两家公司领导层将确保无缝整合，并维护监管合规性和产品质量标准</p>

<p>, /PRNewswire/ -- Arna Pharma Inc <strong>.</strong> and Slate Run Pharmaceuticals announced they have signed an MOU to create a scaled-up U.S.-based specialty pharmaceutical joint venture focused on branded products, 505(b)(2) medicines, and specialized generics.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Arna Pharma Inc 和 Slate Run Pharmaceuticals 宣布他们已签署谅解备忘录，计划创建一个以美国为基地的专业制药合资企业，专注于品牌产品、505(b)(2) 药物和专业仿制药。</p>
</div><p>The joint venture brings together Arna Pharma's development capabilities and portfolio expansion strategy with Slate Run Pharmaceuticals' established U.S. commercial, regulatory, and supply chain infrastructure.</p>
<div class="lb-trans"><p>该合资企业将 Arna Pharma 的开发能力和产品组合扩展战略与 Slate Run Pharmaceuticals 在美国的商业、监管和供应链基础设施相结合。</p>
</div><p>&#34;This represents a significant milestone for Arna Pharma and a powerful step forward in our long-term strategy,&#34; said Ram Iyer, Senior Vice President of Arna Pharma Inc. &#34;By combining Arna's development expertise with Slate Run's proven U.S. commercial and operational infrastructure, we have created a platform that is uniquely positioned to expand specialized generics in high-value therapeutic segments and accelerate market access, reimbursement, and physician engagement.&#34;</p>
<div class="lb-trans"><p>&#34;这标志着 Arna Pharma 的一个重要里程碑，也是我们长期战略向前迈出的重要一步，&#34; Arna Pharma Inc 高级副总裁 Ram Iyer 说。&#34;通过将 Arna 的开发专业知识与 Slate Run 经过验证的美国商业和运营基础设施相结合，我们创建了一个独特的平台，能够在高价值治疗领域扩展专业仿制药，并加速市场准入、报销和医生参与。&#34;</p>
</div><p>Founded in 2014, Slate Run Pharmaceuticals has built a strong U.S. footprint, consisting of an experienced commercial and regulatory team. The joint venture will be well-positioned to scale branded and specialized products efficiently across the U.S. market.</p>
<div class="lb-trans"><p>Slate Run Pharmaceuticals 成立于 2014 年，已在美国建立了强大的市场基础，拥有一支经验丰富的商业和监管团队。该合资企业将能够高效地在美国市场扩展品牌和专业产品。</p>
</div><p>&#34;We are excited to unite our organizations and begin this next chapter together,&#34; said Michael Plessinger, CEO of Slate Run Pharmaceuticals. &#34;This combination strengthens our ability to execute, expand our portfolio, and continue to serve as a trusted U.S. partner for the industry.&#34;</p>
<div class="lb-trans"><p>&#34;我们很高兴能够团结我们的组织，共同开启这一新篇章，&#34; Slate Run Pharmaceuticals 首席执行官 Michael Plessinger 说。&#34;这种结合增强了我们执行的能力，扩展了我们的产品组合，并继续作为行业的可信赖美国合作伙伴。&#34;</p>
</div><p>Leadership from both organizations will work closely to ensure seamless integration, maintain operational continuity, and uphold the highest standards of regulatory compliance, product quality, and patient care.</p>
<div class="lb-trans"><p>两家组织的领导层将紧密合作，以确保无缝整合，保持运营连续性，并遵循最高标准的监管合规、产品质量和患者护理。</p>
</div><p>Arna Pharma Inc and Slate Run Pharmaceuticals welcome engagement with strategic partners, investors, licensors, and portfolio companies interested in collaborating with the combined organization as it executes its growth strategy and builds a leading U.S. specialty pharmaceutical platform.</p>
<div class="lb-trans"><p>Arna Pharma Inc 和 Slate Run Pharmaceuticals 欢迎与战略合作伙伴、投资者、许可方和投资组合公司进行接触，感兴趣的各方可以与合并后的组织合作，共同执行其增长战略，建立领先的美国专业制药平台。</p>
</div><p>For more information please contact:</p>
<div class="lb-trans"><p>如需更多信息，请联系：</p>
</div><ul>
<li><strong><em>Arna Pharma Inc.:</em></strong> Ram Iyer, [email protected]</li>
<li><strong><em>Slate Run Pharmaceuticals LLC</em></strong> : Mike Plessinger, [email protected]</li>
</ul>
<div class="lb-trans"><ul>
<li><strong><em>Arna Pharma Inc.:</em></strong> Ram Iyer, [email protected]</li>
<li><strong><em>Slate Run Pharmaceuticals LLC</em></strong> : Mike Plessinger, [email protected]</li>
</ul>
</div><p><strong>About Arna Pharma Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Arna Pharma Inc.</strong></p>
</div><p>The USA Operation started in 2024 with a vision to create a healthier world, Arna Pharma Inc. blends patent-level innovation with smart, sustainable business practices. Founded by industry experts with a strong focus on innovation and patient outcomes, our commitment to quality and integrity drives us to deliver safe, effective, and reliable therapies.</p>
<div class="lb-trans"><p>美国业务于 2024 年启动，旨在创造一个更健康的世界，Arna Pharma Inc 将专利级创新与智能、可持续的商业实践相结合。由行业专家创立，专注于创新和患者结果，我们对质量和诚信的承诺驱动我们提供安全、有效和可靠的治疗方案。</p>
</div><p>As a fully integrated pharmaceutical organization, Arna Pharma Inc. offers end-to-end capabilities, from formulation development and manufacturing to global marketing and commercialization. Our portfolio emphasizes niche dosage forms and treatments for rare and underserved diseases, reflecting our mission to address unmet medical needs with specialized focus on Respiratory Indications.</p>
<div class="lb-trans"><p>作为一家全面整合的制药组织，Arna Pharma Inc 提供从配方开发和生产到全球营销和商业化的端到端能力。我们的产品组合强调小众剂型和针对罕见和被忽视疾病的治疗，反映了我们以专业化为重点解决未满足医疗需求的使命。</p>
</div><p><strong>About Slate Run Pharmaceuticals:</strong></p>
<div class="lb-trans"><p><strong>关于 Slate Run Pharmaceuticals:</strong></p>
</div><p>Founded in 2014, Slate Run Pharmaceuticals has built a strong and expanding presence in the U.S. generic pharmaceutical market. The company is led by a seasoned leadership team with over 200 years of combined industry experience across commercial operations, regulatory affairs, quality, and supply chain management. Slate Run's team has been directly involved in the selection, FDA approval, commercialization, and supply of a broad portfolio of generic pharmaceuticals spanning multiple therapeutic areas.</p>
<div class="lb-trans"><p>Slate Run Pharmaceuticals 成立于 2014 年，在美国仿制药市场建立了强大且不断扩展的存在。公司由一支经验丰富的领导团队领导，团队成员在商业运营、监管事务、质量和供应链管理方面拥有超过 200 年的行业经验。Slate Run 的团队直接参与了广泛的仿制药组合的选择、FDA 批准、商业化和供应，涵盖多个治疗领域。</p>
</div><p>Today, Slate Run markets more than 30 product families and serves customers across the U.S., including wholesalers, distributors, pharmacies, and healthcare providers. Through disciplined portfolio development, strategic manufacturing partnerships, and a commitment to regulatory compliance and supply reliability, Slate Run is dedicated to expanding patient access to high-quality, affordable medications while driving sustainable growth.</p>
<div class="lb-trans"><p>目前，Slate Run 市场上有超过 30 个产品系列，服务于包括批发商、分销商、药店和医疗服务提供者在内的美国客户。通过严格的产品组合开发、战略制造合作伙伴关系以及对监管合规和供应可靠性的承诺，Slate Run 致力于扩大患者对高质量、可负担药物的获取，同时推动可持续增长。</p>
</div><p>SOURCE Slate Run Pharmaceuticals; Arna Pharma Inc.</p>
<div class="lb-trans"><p>来源：Slate Run Pharmaceuticals; Arna Pharma Inc。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI2Jk5ld3NJdGVtSWQ9Q0w5NjcxNCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjYxMzAwUFJfTkVXU19VU1BSX19fX19DTDk2NzE0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CL96714&amp;Transmission_Id=202602261300PR_NEWS_USPR_____CL96714&amp;DateId=20260226"/></p>

13:00 ETArna Pharma Inc. and Slate Run Pharmaceuticals to form a Joint Venture to Create Scaled-Up U.S. Specialty Pharmaceutical Platform

prnewswire

Salarius Pharmaceuticals

标普全球医疗股指数 ETF - iShares

Verona制药

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

Sarepta医疗

福泰制药

医疗业 ETF - Vanguard

Armata Pharmaceuticals

Invesco Nasdaq Biotechnology ETF

Arna Pharma Inc.与 Slate Run Pharmaceuticals 将成立合资企业，旨在打造一个扩大规模的美国专业制药平台